2003
DOI: 10.1002/chin.200349258
|View full text |Cite
|
Sign up to set email alerts
|

Targeting the HIV trans‐Activation Responsive Region — Approaches Towards RNA‐Binding Drugs

Abstract: Organic chemistryOrganic chemistry Z 0200Targeting the HIV trans-Activation Responsive Region -Approaches Towards RNA-Binding Drugs -[43 refs.]. -(KREBS, A.; LUDWIG, V.; BODEN, O.; GOEBEL*, M. W.; ChemBioChem 4 (2003) 10, 972-978; Inst. Org. Chem., Johann Wolfgang Goethe-Univ., D-60439 Frankfurt/M., Germany; Eng.) -Lindner 49-258

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
8
0

Year Published

2005
2005
2008
2008

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 7 publications
(8 citation statements)
references
References 1 publication
0
8
0
Order By: Relevance
“…Many groups have studied aminoglycoside−RNA interactions using defined RNA targets including the bacterial A-site , HIV TAR RNA , , HIV RRE RNA , , group I introns , the hammerhead ribozyme , the hepatitis delta virus , and RNase P RNAs , . In each case, aminoglycosides inhibited the normal function of the RNA, and the binding site was identified.…”
Section: Resultsmentioning
confidence: 99%
“…Many groups have studied aminoglycoside−RNA interactions using defined RNA targets including the bacterial A-site , HIV TAR RNA , , HIV RRE RNA , , group I introns , the hammerhead ribozyme , the hepatitis delta virus , and RNase P RNAs , . In each case, aminoglycosides inhibited the normal function of the RNA, and the binding site was identified.…”
Section: Resultsmentioning
confidence: 99%
“…Inhibitors of these RNA–protein interactions block full-length transcription and resultant HIV-1 gene expression, and thus are potential candidates for anti-HIV therapies. Despite much effort to date, no small molecule inhibitors [reviewed in Refs ( 20 )] have emerged as clinical candidates.…”
Section: Introductionmentioning
confidence: 99%
“…The interaction between the transactivation response element (TAR 1 ) RNA (13) from the human immunodeficiency type I virus (HIV-1) and the viral transactivator protein (Tat) is a paradigm for understanding the rules of RNA adaptive recognition (1,5,8,14) and a primary target for developing anti-HIV therapeutics (15)(16)(17)(18). Several high-resolution structures have been reported for HIV-1 TAR (Figure 1), including the free form (19) and bound to divalent cations (20), peptide mimics of Tat (21,22), and six distinct small molecules containing a different number of cationic groups designed to inhibit its interaction with Tat (23)(24)(25)(26).…”
mentioning
confidence: 99%